Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on May 1, 2026, to eight new employees to purchase up to 162,100 shares under its 2023 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on May 1, 2026, to eight new employees to purchase up to 162,100 shares under its 2023 Inducement Plan. The stock options vest over four years: 25% at one year, then 1/48th monthly over the following 36 months, subject to continued service.
Details
News Market Reaction – SNDX
On May 7, the first trading day after this news, SNDX closed 0.53% below the previous close.
Data tracked by StockTitan Argus for the May 7 session.
Key Figures
- Inducement option shares
- 162,100 shares
- Options to purchase common stock granted May 1, 2026
- New employees
- 8
- Recipients of inducement awards under 2023 Inducement Plan
- Vesting period
- 4 years
- Total vesting duration for inducement stock options
- Cliff vesting
- 25%
- Portion vesting on one-year anniversary of vesting commencement
- Monthly vesting fraction
- 1/48th
- Portion vesting monthly after first year
- Post-cliff vesting period
- 36 months
- Monthly vesting duration following first-year cliff
Historical Context
-
Strong Q1 2026 revenue growth but continuing net loss and high R&D and SG&A.
-
Announcement of Q1 2026 results date and investor conference call details.
-
Inducement stock options for up to 228,500 shares to eight new employees.
-
Inducement options for up to 81,600 shares for three new employees.
-
Q4 and FY25 revenue growth from Revuforj and Niktimvo with narrowed losses.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
inducement awards financial
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026, the Company granted inducement awards to purchase up to 162,100 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.